A phase I dose-finding study of the novel toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3683-3691

  Northfelt, Donald W ^a   Ramanathan, Ramesh K ^b,c   Cohen, Peter A ^a   Von Hoff, Daniel D ^a,b,c   Weiss, Glen J ^b,c,d   Dietsch, Gregory N ^b   Manjarrez, Kristi L ^b   Randall, Tressa D ^b   Hershberg, Robert M ^b  

^a MAYO CLINIC   (United States)

^b Virginia G Piper Cancer Center ^*  (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VTX 2337; BENZAZEPINE DERIVATIVE; TLR8 PROTEIN, HUMAN; VTX-2337;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER PAIN; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CYTOKINE RELEASE SYNDROME; DECREASED APPETITE; DEHYDRATION; DISEASE DURATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE TOXICITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOMODULATION; INJECTION SITE REACTION; INNATE IMMUNITY; LIVER FAILURE; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; UREMIA; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING; AGONISTS; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAZEPINES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; TOLL-LIKE RECEPTOR 8; TREATMENT OUTCOME;

EID: 84904387563     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0392     Document Type: Article

References (23)

1. Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin Immunol 2006;18:136-42. (Pubitemid 43248742)
2. Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008;13:859-75.
3. Wang RF, Miyahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008;27:181-9.
4. Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol 2009;6:257-65.
5. Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Inglefield JR, Hook D, et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell Immunol 2006;243:48-57.
6. Lu H, Dietsch GN, Matthews M-AH, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012;18:499-509.
7. Gorden KB, Qiu X, Binsfield CA, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006;177:6584-7. (Pubitemid 44715019)
8. Liu J, Congfeng X, Li-Chung H, Yunping L, Rong X, Tsung-Hsien C. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol 2010;47:1083-90.
9. Gibbard RJ, Morley PJ, Gay NJ. Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling. J Biol Chem 2006;281:27503-11. (Pubitemid 44401777)
10. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 2013;339:1426-9.
11. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005;174:1259-68.
12. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606.
13. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol 2010;40:2667-76.
14. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
15. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol 2008:71-86.
16. Philbin VJ, Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans 2007;35(Pt 6):1485-91.
17. Tarhini AA, Kirkwood JM, Krieg AM. Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opin Drug Discov 2009;4:587-603.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007;13:6168-74. (Pubitemid 350075077)
20. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13:7119-25. (Pubitemid 350276897)
21. O'Neill LAJ, Golenbock D, Bowie A. The history of toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013;13:453-60.
22. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells an dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother 2013;62:1346-57.
23. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. NEJM 2012;366:925-31.